Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
DEI Awards
Innovation Awards
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Subscribe
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
DEI Awards
Innovation Awards
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug reimbursement
Providers
CMS' proposed 340B reimbursement cut—who wins, and who loses?
DSHs are expected to see a 5.8% net reduction in OPPS revenue under the proposal, while for-profits are expecting a 7.4% net increase.
Dave Muoio
Jul 29, 2026 5:00pm
Proposed CY2027 OPPS rule brings 340B, site-neutral pay overhaul
Jul 6, 2026 1:00pm
Optum Rx rolls out new brand drug pricing model for pharmacies
Sep 17, 2025 3:55am
CMS unveils details on coverage for new Alzheimer's meds
Jun 23, 2023 11:00am
Hospitals' 340B participation linked to reduced biosimilar use
May 2, 2023 1:13pm
Political headwinds grow against CMMI drug price model
Mar 13, 2023 8:30am
